Atkinson Edward Morrow III

EVP Atkinson Morrow sells 2,848 VRTX shares for $1.4M; 2 of 3 prior VRTX sales well-timed at 90d.

Atkinson Edward Morrow III, Chief Technical Operations Officer, executed 2 separate sales totaling 2,848 shares for $1,381,089.82 on February 17–18, 2026, at an average price of $484.93, reducing his holdings by 12.1%. His prior 3 VRTX sales showed mixed timing outcomes: the November 2025 sale preceded a 13.1% 90-day gain (poorly timed), while the February 2025 and June 2024 sales saw declines at the 90-day horizon (2 of 3 well-timed). Current stock price of $469.27 sits 8.7% below the 52-week high and has risen 6.2% over 30 days and 10.0% over 90 days—conditions distinct from the downturns that followed his prior well-timed exits. VRTX fundamentals remain solid: $3.1B quarterly revenue, $1.1B net income, and 8.9% annual growth at a 14.60 P/E, suggesting no obvious deterioration in business health that would explain the sale as a risk-reduction move.

EVP Morrow sells 2,500 VRTX shares at $434.58; prior sales at this ticker show 100% well-timed pattern at 90d mark.

Atkinson Edward Morrow III, EVP and Chief Technical Operations Officer, sold 2,500 shares of Vertex Pharmaceuticals at $434.58 on 2025-11-17, reducing his holdings by 12.9% from 19,352 to 16,852 shares. His prior trades at VRTX (2 of 2 prior sells) were both well-timed at the 90-day mark, with post-sale returns of -6.4% and -1.5%—a 100% timing success rate at this ticker. The stock has since fallen 18.0% from its 52-week high of $513.76 and currently trades at $421.03, suggesting this latest sale aligns with his demonstrated pattern of selling ahead of declines. While Vertex shows fundamental strength (11.7% annual revenue growth, $3.1B quarterly revenue, P/E of 29.08), the company posted a full-year net loss in its most recent fiscal year, and the insider's consistent pattern of well-timed exits at this ticker warrants tracking as his sales have historically preceded negative 90-day performance.

EVP Atkinson Morrow sold 2,650 VRTX shares at $475.34 for $1.3M, reducing stake 12.0%; stock up 8.7% in 30 days.

Atkinson Morrow III, EVP of Chief Technical Operations, sold 2,650 shares (representing a 12.0% reduction from pre-transaction holdings of 22,002 shares) on 2025-02-27 at $475.34 per share. The stock has appreciated 8.7% over the 30 days following the sale and currently trades at $479.79, near the upper half of its 52-week range. Notably, his one prior sale at VRTX on 2024-06-12 resulted in a 90-day return of -1.5%, marking a well-timed exit before subsequent decline. However, his cross-ticker track record shows mixed timing: only 1 prior open-market sale with an average 90-day return of -1.5%, though the 100.00% well-timed rate reflects the limited sample. The company remains unprofitable on a full-year basis despite strong recent fundamentals: $2.8B quarterly revenue (annual growth +11.7%) and $1.0B quarterly net income. This sale appears discretionary rather than portfolio-maintenance, as it represents a meaningful position reduction, warranting observation of whether the executive views current valuations as opportune for reducing exposure.